(Q46145068)

English

Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations

scientific article published in December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

author name string

Stefano Lello

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

Grazia Primavera

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

Laura Colonna

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

Giorgio Vittori

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

Francesca Guardianelli

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

Roberto Sorge

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

Desanka Raskovic

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

publication date

1 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

Gynecological Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

24

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

12

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

718-723

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Dermatologic manifestations of polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Progestogens with antiandrogenic properties

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Belara--a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Clinical assessment of body hair growth in women

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Drospirenone in combination with estrogens: for contraception and hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Newer progestogens

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Conception and pharmacodynamic profile of drospirenone

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Pharmacology of estrogens and progestogens: influence of different routes of administration

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Androgens and antiandrogens

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity

1 reference

https://api.crossref.org/works/10.1080%2F09513590802454943

21 January 2018

Identifiers

10.1080/09513590802454943

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

release_fbny3f2darewleay5b42d6nrry

1 reference

https://api.fatcat.wiki/v0/release/fbny3f2darewleay5b42d6nrry

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19172543

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46145068&oldid=2094929838"